Anti-remodeling therapies in pulmonary arterial hypertension
Authors:
Top Cited Papers
- 19 June 2025
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 46 (7) , 674-691
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Tet Methylcytosine Dioxygenase 2 (TET2) Mutation Drives a Global Hypermethylation Signature in Patients With Pulmonary Arterial Hypertension (PAH): Correlation With Altered Gene Expression Relevant to a Common T Cell PhenotypeComprehensive Physiology, 2025
- Therapeutic potential of allosteric HECT E3 ligase inhibitionCell, 2025
- CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trialPulmonary Circulation, 2024
- Endothelial cell senescence exacerbates pulmonary hypertension by inducing juxtacrine Notch signaling in smooth muscle cellsiScience, 2023
- Targeted treprostinil delivery inhibits pulmonary arterial remodelingEuropean Journal of Pharmacology, 2022
- Phenotypic Diversity of Vascular Smooth Muscle Cells in Pulmonary Arterial HypertensionChest, 2022
- PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinomaThe International Journal of Biochemistry & Cell Biology, 2018
- FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertensionJournal of Molecular Medicine, 2017
- Long-term safety and efficacy of imatinib in pulmonary arterial hypertensionThe Journal of Heart and Lung Transplantation, 2015
- Interaction of Tacrolimus (FK506) and Its Metabolites with FKBP and CalcineurinBiochemical and Biophysical Research Communications, 1994